Revolution Medicines (RVMD) Current Leases (2020 - 2026)

Revolution Medicines' Current Leases history runs 7 years deep, the most recent figure standing at $16.6 million for Q1 2026.

• On a quarterly basis, Current Leases rose 27.98% year-over-year to $16.6 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 27.98% increase from a year earlier, with the FY2025 full-year figure at $16.5 million, up 27.94% from the prior year.
• Current Leases advanced to $16.6 million in Q1 2026 per RVMD's latest filing, from $16.5 million in the prior quarter.
• Across five years, Current Leases topped out at $16.6 million in Q1 2026 and bottomed at $5.7 million in Q2 2023.
• The 5-year median for Current Leases is $8.2 million (2024), against an average of $9.7 million.
• Across the five-year window, Current Leases decreased 17.98% in 2023 and surged 94.45% in 2025, its largest moves.
• Year by year, Current Leases stood at $6.8 million in 2022, then grew by 8.8% to $7.4 million in 2023, then jumped by 74.68% to $12.9 million in 2024, then grew by 27.94% to $16.5 million in 2025, then climbed by 0.86% to $16.6 million in 2026.
• Per Business Quant, the three latest RVMD Current Leases figures stand at $16.6 million (Q1 2026), $16.5 million (Q4 2025), and $16.3 million (Q3 2025).